Bio-Rad Laboratories announced its financial results for the first quarter ended March 31, 2026. This filing provides investors with the company's latest quarterly performance data through an accompanying press release and supplemental earnings presentation.

Bio-Rad Laboratories stockholders approved an amendment to the 2017 Incentive Award Plan, increasing the common stock reserve by 335,000 shares and extending the plan's expiration to 2036. Notably, shareholders rejected a proposal to alter the company's dual-class capital structure, thereby maintaining the current governance and voting power framework. These results, alongside the election of directors and ratification of auditors, signal investor support for the company's existing leadership and compensation structures.

Bio-Rad Laboratories provided an update on its investment in Sartorius AG to incorporate Sartorius's 2025 financial results, which reported €3,538.1 million in sales revenue and €230.4 million in net profit. This disclosure is relevant to investors as it updates the performance and financial health of a significant investment held by Bio-Rad.

Bio-Rad Laboratories announced its financial results for the quarter ended December 31, 2025. This filing is material to investors as it provides the official update on the company's operational performance and financial condition for the final quarter of the year.

Bio-Rad Laboratories, Inc. announced its financial results for the quarter ended September 30, 2025, through a press release and supplemental earnings presentation. This disclosure provides the essential quarterly performance data necessary for investors to evaluate the company's recent financial health and operational trajectory.